1. Home
  2. PHUN vs SKYE Comparison

PHUN vs SKYE Comparison

Compare PHUN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHUN
  • SKYE
  • Stock Information
  • Founded
  • PHUN 2009
  • SKYE 2012
  • Country
  • PHUN United States
  • SKYE United States
  • Employees
  • PHUN N/A
  • SKYE N/A
  • Industry
  • PHUN EDP Services
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • PHUN Technology
  • SKYE Health Care
  • Exchange
  • PHUN Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • PHUN 88.8M
  • SKYE 80.7M
  • IPO Year
  • PHUN N/A
  • SKYE N/A
  • Fundamental
  • Price
  • PHUN $3.92
  • SKYE $3.06
  • Analyst Decision
  • PHUN Strong Buy
  • SKYE Buy
  • Analyst Count
  • PHUN 3
  • SKYE 6
  • Target Price
  • PHUN $13.00
  • SKYE $18.67
  • AVG Volume (30 Days)
  • PHUN 1.1M
  • SKYE 207.1K
  • Earning Date
  • PHUN 03-11-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • PHUN N/A
  • SKYE N/A
  • EPS Growth
  • PHUN N/A
  • SKYE N/A
  • EPS
  • PHUN N/A
  • SKYE N/A
  • Revenue
  • PHUN $3,537,000.00
  • SKYE N/A
  • Revenue This Year
  • PHUN N/A
  • SKYE N/A
  • Revenue Next Year
  • PHUN $93.33
  • SKYE N/A
  • P/E Ratio
  • PHUN N/A
  • SKYE N/A
  • Revenue Growth
  • PHUN N/A
  • SKYE N/A
  • 52 Week Low
  • PHUN $2.85
  • SKYE $2.31
  • 52 Week High
  • PHUN $17.99
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • PHUN 41.98
  • SKYE 50.73
  • Support Level
  • PHUN $3.56
  • SKYE $2.60
  • Resistance Level
  • PHUN $4.04
  • SKYE $3.54
  • Average True Range (ATR)
  • PHUN 0.22
  • SKYE 0.49
  • MACD
  • PHUN -0.01
  • SKYE 0.02
  • Stochastic Oscillator
  • PHUN 46.71
  • SKYE 30.81

About PHUN Phunware Inc.

Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: